Thanks for all the responses. If I might, address the board on some secondary points: time permitting, could folks summarize the merits of the technology from both GERN and ACTC, and comment on the markets they target and growth potential?
Additionally, anything on "business model" and "quality of management" would be great as well.
Thanks in advance....
I have not bailed yet...fwiw.
I haven't followed STEM very much so I won't comment on it.
Between GERN and ACTC, ACTC wins hands down right now. It sure looks like they are getting remarkable results with their stem cell patients. Things are looking up.
GERN, on the other hand, has nothing much to look forward to. I strongly suspect that after mis-management sucks the remaining $$$ out of the bank with their lavish compensation, it will go belly-up.
I'm certain that many of us wish we had gotten out of GERN years ago.
Of course, IMO.
Hey Blackster just check out your underperforming ACTC PPS to find a management with absolutely no clue.(Except for insider selling and dilution extraordinaire.)
Prices there are falling again as usual.
Don't believe it?
Just check the current PPS!!!
Of course, IMO.
Geron certainly has had problems but ACTC? LOL
People are rightly upset her with a 50 million self offering for Geron but
Yes dilution does dilute what should have been much better day!
2007 ACTC outstanding shares was 47,232,136
2013 ACTC outstanding shares was 2,438,530,433
the ~Average~ increase ( ACTC dilution) over 6 years was Per Second = 13 shares ..... Per day = 1,123,200......... Per Week = 7,862,400........ Per Month = 31,449,600.............................
An exceptional volume of 18 million today for ACTC ONLY covers less than 3 weeks of dilution.
Picture ACTC a